Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes

Diabetes

Volumn 62, Issue 5, 2013, Pages 1656-1664

  Piemonti, Lorenzo ^a   Everly, Matthew J ^b   Maffi, Paola ^a   Scavini, Marina ^a   Poli, Francesca ^c   Nano, Rita ^a   Cardillo, Massimo ^c   Melzi, Raffaella ^a   Mercalli, Alessia ^a   Sordi, Valeria ^a   Lampasona, Vito ^d   De Arias, Alejandro Espadas ^c   Scalamogna, Mario ^c   Bosi, Emanuele ^a,e   Bonifacio, Ezio ^f   Secchi, Antonio ^a,e   Terasaki, Paul I ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b TERASAKI FOUNDATION LABORATORY   (United States)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d Genomic Unit for the Diagnosis of Human Pathologies   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; BASILIXIMAB; CELL MARKER; DONOR SPECIFIC ALLOANTIBODY; HLA A ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INSULINOMA ASSOCIATED PROTEIN 2 ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ZINC TRANSPORTER; ZINC TRANSPORTER TYPE 8 ANTIGEN;

ADULT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HLA TYPING; HUMAN; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK FACTOR; TREATMENT OUTCOME;

ADULT; ANTILYMPHOCYTE SERUM; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; ISOANTIBODIES; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; MYCOPHENOLIC ACID; PROGNOSIS; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 84876551801     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-1258     Document Type: Article

References (48)

1. Stegall MD, Lafferty KJ, Kam I, Gill RG. Evidence of recurrent autoimmunity in human allogeneic islet transplantation. Transplantation 1996;61:1272-1274 (Pubitemid 26134783)
2. Worcester Human Islet Transplantation Group. Autoimmunity after isletcell allotransplantation. N Engl J Med 2006;355:1397-1399
3. Toso C, Isse K, Demetris AJ, et al. Histologic graft assessment after clinical islet transplantation. Transplantation 2009;88:1286-1293
4. Lacotte S, Berney T, Shapiro AJ, Toso C. Immune monitoring of pancreatic islet graft: towards a better understanding, detection and treatment of harmful events. Expert Opin Biol Ther 2011;11:55-66
5. Hilbrands R, Huurman VA, Gillard P, et al. Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes 2009;58:2267-2276
6. Huurman VA, Hilbrands R, Pinkse GG, et al. Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS ONE 2008;3:e2435
7. Roelen DL, Huurman VA, Hilbrands R, et al. Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation. Clin Exp Immunol 2009;156:141-148
8. Roep BO, Stobbe I, Duinkerken G, et al. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients. Diabetes 1999;48:484-490 (Pubitemid 29106860)
9. van Kampen CA, van de Linde P, Duinkerken G, et al. Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation 2005;80:118-126 (Pubitemid 40980904)
10. Huurman VA, Velthuis JH, Hilbrands R, et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant 2009;9:382-388
11. Mohanakumar T, Narayanan K, Desai N, et al. A significant role for histocompatibility in human islet transplantation. Transplantation 2006;82:180-187 (Pubitemid 44126814)
12. Caro-Oleas JL, González-Escribano MF, Gentil-Govantes MA, et al. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Transplantation 2012;94:338-344
13. Hirai T, Kohei N, Omoto K, Ishida H, Tanabe K. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transpl Int 2012;25:925-934
14. Hoshino J, Kaneku H, Everly MJ, Greenland S, Terasaki PI. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation 2012;93:1173-1178
15. Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. Natural history of type 1 diabetes. Diabetes 2005;54(Suppl. 2):S25-S31 (Pubitemid 43343328)
16. Jaeger C, Hering BJ, Hatziagelaki E, Federlin K, Bretzel RG. Glutamic acid decarboxylase antibodies are more frequent than islet cell antibodies in islet transplanted IDDM patients and persist or occur despite immunosuppression. J Mol Med (Berl) 1999;77:45-48 (Pubitemid 29146181)
17. Jaeger C, Brendel MD, Hering BJ, Eckhard M, Bretzel RG. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 1997;46:1907-1910 (Pubitemid 27456431)
18. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005;293:830-835 (Pubitemid 40250366)
19. Bosi E, Braghi S, Maffi P, et al. Autoantibody response to islet transplantation in type 1 diabetes. Diabetes 2001;50:2464-2471 (Pubitemid 33642763)
20. Campbell PM, Salam A, Ryan EA, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007;7:1242-1248 (Pubitemid 46643123)
21. Kessler L, Parissiadis A, Bayle F, et al.; GRAGIL Study Group. Evidence for humoral rejection of a pancreatic islet graft and rescue with rituximab and IV immunoglobulin therapy. Am J Transplant 2009;9:1961-1966
22. Rickels MR, Kamoun M, Kearns J, Markmann JF, Naji A. Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. J Clin Endocrinol Metab 2007;92:2410-2414 (Pubitemid 47037334)
23. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006;355:1318-1330 (Pubitemid 44465460)
24. Piemonti L, Maffi P, Monti L, et al. Beta cell function during rapamycin monotherapy in long-term type 1 diabetes. Diabetologia 2011;54:433-439
25. Kellar KL, Iannone MA. Multiplexed microsphere-based flow cytometric assays. Exp Hematol 2002;30:1227-1237 (Pubitemid 35287575)
26. Colombo MB, Haworth SE, Poli F, et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom 2007;72:465-471 (Pubitemid 350086253)
27. Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964;204:998-1000
28. Gebel HM, Bray RA. The evolution and clinical impact of human leukocyte antigen technology. Curr Opin Nephrol Hypertens 2010;19:598-602
29. Bonifacio E, Genovese S, Braghi S, et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 1995;38:816-822
30. Bonifacio E, Lampasona V, Genovese S, Ferrari M, Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol 1995;155:5419-5426
31. Lampasona V, Petrone A, Tiberti C, et al.; Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study Group. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care 2010;33:104-108
32. Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51:846-852
33. Occhipinti M, Lampasona V, Vistoli F, et al. Zinc transporter 8 autoantibodies increase the predictive value of islet autoantibodies for function loss of technically successful solitary pancreas transplant. Transplantation 2011;92:674-677
34. Braghi S, Bonifacio E, Secchi A, Di Carlo V, Pozza G, Bosi E. Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes 2000;49:218-224 (Pubitemid 30071000)
35. Otten HG, Verhaar MC, Borst HP, Hené RJ, van Zuilen AD. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012;12:1618-1623
36. Eng HS, Bennett G, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008;8:2335-2342
37. Riethmüller S, Ferrari-Lacraz S, Müller MK, et al. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation. Transplantation 2010;90:160-167
38. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009;87:1681-1688
39. McAlister CC, Gao ZH, McAlister VC, et al. Protective anti-donor IgM production after crossmatch positive liver-kidney transplantation. Liver Transpl 2004;10:315-319 (Pubitemid 38240133)
40. Fradet Y, Roy R, Lachance JG, Noël R. Kidney graft survival: role of blood transfusions and lymphocytotoxic antibodies. Clin Nephrol 1982;18:69-73 (Pubitemid 12041699)
41. Melero J, Tarragó D, Núñez-Roldán A, Sánchez B. Human polyreactive IgM monoclonal antibodies with blocking activity against self-reactive IgG. Scand J Immunol 1997;45:393-400 (Pubitemid 27138279)
42. Kerman RH, Susskind B, Buyse I, et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999;68:1855-1858 (Pubitemid 30027337)
43. Vendrame F, Pileggi A, Laughlin E, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010;59:947-957
44. Ferrari-Lacraz S, Berney T, Morel P, et al. Low risk of anti-human leukocyte antigen antibody sensitization after combined kidney and islet transplantation. Transplantation 2008;86:357-359
45. Campbell PM, Senior PA, Salam A, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007;7:2311-2317 (Pubitemid 47347848)
46. Cardani R, Pileggi A, Ricordi C, et al. Allosensitization of islet allograft recipients. Transplantation 2007;84:1413-1427 (Pubitemid 350294716)
47. Sibley RK, Sutherland DE, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft. A light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985;53:132-144 (Pubitemid 15049005)
48. Sibley RK, Sutherland DE. Pancreas transplantation. An immunohistologic and histopathologic examination of 100 grafts. Am J Pathol 1987;128:151-170 (Pubitemid 17094345)